anmelden
BX Swiss TOP 30 CHF
1.411,05
PKT
+6,66
PKT
+0,47
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 01.02.16 | Zurich Insurance overweight | Barclays Capital | |
| 01.02.16 | Roche buy | Société Générale Group S.A. (SG) | |
| 01.02.16 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 01.02.16 | UBS Underperform | BNP PARIBAS | |
| 01.02.16 | UBS Neutral | BNP PARIBAS | |
| 01.02.16 | Roche buy | UBS AG | |
| 01.02.16 | Roche buy | HSBC | |
| 01.02.16 | UBS Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.02.16 | UBS Neutral | Goldman Sachs Group Inc. | |
| 01.02.16 | Novartis buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 29.01.16 | Roche Outperform | Credit Suisse Group | |
| 29.01.16 | Roche Hold | S&P Capital IQ | |
| 29.01.16 | Roche overweight | JP Morgan Chase & Co. | |
| 29.01.16 | Novartis buy | HSBC | |
| 29.01.16 | ABB (Asea Brown Boveri) Sell | Goldman Sachs Group Inc. | |
| 28.01.16 | Novartis Hold | S&P Capital IQ | |
| 28.01.16 | Novartis Neutral | BNP PARIBAS | |
| 28.01.16 | Novartis Halten | Independent Research GmbH | |
| 28.01.16 | Novartis Hold | Société Générale Group S.A. (SG) | |
| 28.01.16 | Novartis overweight | JP Morgan Chase & Co. | |
| 28.01.16 | Novartis Underweight | Barclays Capital | |
| 27.01.16 | Richemont buy | UBS AG | |
| 27.01.16 | Zurich Insurance Neutral | UBS AG | |
| 27.01.16 | Givaudan Hold | HSBC | |
| 27.01.16 | Zurich Insurance verkaufen | Independent Research GmbH | |
| 27.01.16 | Swiss Re Equal-Weight | Morgan Stanley | |
| 27.01.16 | UBS buy | Citigroup Corp. | |
| 27.01.16 | UBS buy | Citigroup Corp. | |
| 27.01.16 | Zurich Insurance Underperform | Bernstein Research | |
| 26.01.16 | Nestlé buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 25.01.16 | UBS Halten | Independent Research GmbH | |
| 25.01.16 | Swiss Re Neutral | JP Morgan Chase & Co. | |
| 25.01.16 | Roche buy | UBS AG | |
| 25.01.16 | Novartis overweight | JP Morgan Chase & Co. | |
| 25.01.16 | Roche overweight | JP Morgan Chase & Co. | |
| 25.01.16 | Zurich Insurance overweight | Barclays Capital | |
| 25.01.16 | Zurich Insurance Neutral | BNP PARIBAS | |
| 22.01.16 | Novartis buy | UBS AG | |
| 22.01.16 | ABB (Asea Brown Boveri) Neutral | UBS AG | |
| 22.01.16 | Richemont Outperform | Credit Suisse Group |